Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.16 -2.5%	$1.26	$0.86 ▼ $3.78	$260.29M	0.31	3.26 million shs	1.98 million shs
AXSM Axsome Therapeutics	$107.50 +2.0%	$106.64	$72.21 ▼ $139.13	$5.19B	0.46	668,793 shs	570,536 shs
BEAM Beam Therapeutics	$19.18 -4.1%	$17.62	$13.53 ▼ $35.25	$2.01B	2.07	1.52 million shs	2.83 million shs
CRSP CRISPR Therapeutics	$51.19 -1.9%	$40.95	$30.04 ▼ $63.68	$4.51B	1.82	1.90 million shs	2.18 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+0.85%	-16.20%	-16.78%	-43.87%
AXSM Axsome Therapeutics	0.00%	+1.93%	-5.86%	+6.96%	+28.45%
BEAM Beam Therapeutics	0.00%	+19.17%	+7.75%	+30.85%	-13.26%
CRSP CRISPR Therapeutics	0.00%	+9.82%	+24.59%	+61.07%	-1.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.9988 of 5 stars	4.5	1.0	0.0	0.6	3.3	0.6
AXSM Axsome Therapeutics	4.749 of 5 stars	4.5	1.0	4.5	2.3	4.2	0.6
BEAM Beam Therapeutics	2.4888 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
CRSP CRISPR Therapeutics	2.8433 of 5 stars	4.3	1.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	627.97% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	60.31% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	154.17% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	40.16% Upside

Current Analyst Ratings Breakdown

Latest CRSP, ALLO, AXSM, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,686.34	N/A	N/A	$2.01 per share	0.58
AXSM Axsome Therapeutics	$385.69M	13.72	N/A	N/A	$1.18 per share	91.10
BEAM Beam Therapeutics	$63.52M	30.36	N/A	N/A	$8.86 per share	2.16
CRSP CRISPR Therapeutics	$37.31M	118.49	N/A	N/A	$22.64 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	38.12	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)

Latest CRSP, ALLO, AXSM, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
AXSM Axsome Therapeutics	3.48	2.03	1.96
BEAM Beam Therapeutics	N/A	8.81	8.81
CRSP CRISPR Therapeutics	N/A	15.64	15.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
AXSM Axsome Therapeutics	81.49%
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
AXSM Axsome Therapeutics	22.40%
BEAM Beam Therapeutics	3.50%
CRSP CRISPR Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.82 million	Optionable

CRSP, ALLO, AXSM, and BEAM Headlines

Recent News About These Companies

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

July 7 at 7:01 PM | zacks.com

Cambridge Investment Research Advisors Inc. Grows Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

July 4 at 3:19 AM | marketbeat.com

CRSP - CRISPR Therapeutics AG Sustainability - Morningstar

July 3, 2025 | morningstar.comM

H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update

July 3, 2025 | msn.com

2 Beaten-Down Stocks With Massive Upside Potential

July 3, 2025 | fool.com

2 Growth Stocks to Buy Hand Over Fist in July

July 2, 2025 | fool.com

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025

June 30, 2025 | finance.yahoo.com

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 7.1% - Should You Buy?

June 30, 2025 | marketbeat.com

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

June 30, 2025 | zacks.com

Sumitomo Mitsui Trust Group Inc. Sells 205,787 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

June 30, 2025 | marketbeat.com

Piper Sandler Remains a Buy on Crispr Therapeutics AG (CRSP)

June 29, 2025 | theglobeandmail.com

CRISPR Therapeutics' (CRSP) Overweight Rating Reaffirmed at Piper Sandler

June 29, 2025 | americanbankingnews.com

CRSP - CRISPR Therapeutics AG Ownership - Morningstar

June 28, 2025 | morningstar.comM

Clear Street Downgrades CRISPR Therapeutics (CRSP)

June 28, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Increases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

June 28, 2025 | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for CRISPR Therapeutics (NASDAQ:CRSP)

June 28, 2025 | americanbankingnews.com

CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know

June 27, 2025 | finance.yahoo.com

CRSP CRISPR Therapeutics AG - Seeking Alpha

June 27, 2025 | seekingalpha.com

CRISPR Therapeutics (NASDAQ:CRSP) Dow Jones Industrial Average

June 27, 2025 | kalkinemedia.comK

Piper Sandler Reaffirms "Overweight" Rating for CRISPR Therapeutics (NASDAQ:CRSP)

June 27, 2025 | marketbeat.com

Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?

June 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
The Apple Comeback Will Be Better Than the Setback
By Gabriel Osorio-Mazilli | July 4, 2025
View The Apple Comeback Will Be Better Than the Setback
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
By Chris Markoch | June 24, 2025
View HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

CRSP, ALLO, AXSM, and BEAM Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.16 -0.03 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 +0.00 (+0.09%)

As of 07:45 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics NASDAQ:AXSM

$107.50 +2.06 (+1.95%)

As of 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Beam Therapeutics NASDAQ:BEAM

$19.18 -0.83 (-4.15%)

Closing price 04:00 PM Eastern

Extended Trading

$19.33 +0.15 (+0.76%)

As of 07:57 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$51.19 -0.98 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$50.84 -0.34 (-0.67%)

As of 08:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time